USPTO serial 79377769
ACCENTIS
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- MILLER, CHARLES FREDERICK
- Law office
- TMO LAW OFFICE 112
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ACCENTIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kevan L. Morgan
Kevan L. Morgan Seed IP Law Group LLP701 Fifth AvenueSuite 5400Seattle, WA 98104Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical and veterinary purposes; diagnostic preparations for medical and veterinary purposes, in particular recombinantly or synthetically produced antigens, lysates of microorganisms, preparations for conducting serological tests, biochemical preparations for conducting confirmatory tests; diagnostic preparations for medical and veterinary purposes, in particular immobilised proteins on a carrier, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; diagnostic preparations for medical and veterinary purposes, in particular immobilised proteins on a carrier material, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; diagnostic preparations for medical and veterinary purposes, in particular immobilised peptides or immobilised polypeptides on a carrier, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; diagnostic preparations for medical and veterinary purposes, in particular immobilised peptides or immobilised polypeptides on a carrier material, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; immunoserological test kits, comprising reagents that are matched to one another for conducting immunoserological tests for medical and veterinary purposes for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes, comprising reagents that are matched to one another for conducting diagnostic tests for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes, comprising immobilised proteins on a carrier, in particular a microbead or a nanobead for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes, comprising immobilised proteins on a carrier material, in particular a microbead or a nanobead for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes, comprising immobilised peptides or immobilised polypeptides on a carrier, in particular a microbead or a nanobead for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes, comprising immobilised peptides or immobilised polypeptides on a carrier material, in particular a microbead or a nanobead for use in disease, disorder, medical or veterinary condition testing and genetic testing; test kits for medical and veterinary diagnostic purposes, comprising surface modified or surface activated microbeads or nanobeads enabling the coupling of proteins, polypeptides and peptides for use in disease, disorder, medical or veterinary condition testing and genetic testing; reagents for medical and veterinary diagnostic purposes; reagents for medical and veterinary diagnostic purposes, in particular immobilised proteins on a carrier, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; reagents for medical and veterinary diagnostic purposes, in particular immobilised proteins on a carrier material, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; reagents for medical and veterinary diagnostic purposes, in particular immobilised peptides or immobilised polypeptides on a carrier, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; reagents for medical and veterinary diagnostic purposes, in particular immobilised peptides or immobilised polypeptides on a carrier material, in particular a biochip, microbead, nanobead, microsphere, test strip, blot, microtiter plate or membrane in the field of autoimmune diagnostics, detection of autoimmune diseases, infection diagnostics, detection of infectious diseases and agents, allergy diagnostics, detection of allergies and allergens, antigen detection, molecular genetic diagnostics, detection of neurological diseases, detection of food intolerances, detection of metabolic diseases, detection of endocrine disorders, detection of inflammation and inflammatory agents, or detection of cancers; all aforementioned goods being not for or in connection with ophthalmic and ophthalmological pharmaceutical products. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 21, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 21, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 20, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 15, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 26, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 24, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 10, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 10, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 10, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 18, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 18, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 18, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 21, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 21, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 6, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 5, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 19, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 5, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 31, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |